Expert review of pharmacoeconomics & outcomes research · 2026
Health impact and cost-effectiveness analysis of introducing a national immunization program with 21-valent versus 20-valent pneumococcal conjugate vaccines for adults ≥65 years of age in Denmark.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sharomi Oluwaseun, Oidtman Rachel J, Lang John C, Bakker Kevin M, Malik Tufail, Meleleo Giulio, Kantsø Line Roesgaard, Theisen Honore Emilie, Holm Vinfeldt Maja, Flindhardt Simone Ruth, Tsoumani Eleana
Аннотация
BACKGROUND: Streptococcus pneumoniae is a vaccine-preventable bacterium responsible for invasive pneumococcal disease (IPD). Adults ≥65 are most susceptible to IPD, and pneumococcal vaccines may reduce morbidity and mortality.
RESEARCH DESIGN AND METHODS: A deterministic dynamic transmission model evaluated the health impact and cost-effectiveness of a 21-valent pneumococcal conjugate vaccine (PCV; PCV21) national immunization program (NIP) compared with a 20-valent PCV (PCV20) NIP for adults ≥65 in Denmark from 2020 through 2120. Cumulative pneumococcal disease cases and deaths averted, quality-adjusted life years (QALYs), and societal healthcare costs are reported. An incremental cost-effectiveness ratio (ICER) was calculated comparing a PCV21 NIP to a PCV20 NIP.
RESULTS: Compared to a PCV20 NIP, a PCV21 NIP would avert an additional 29,309 non-bacteremic pneumococcal pneumonia (NBPP) cases, 9,625 hospitalizations (IPD and inpatient NBPP), 627 IPD cases, and 1,312 deaths over 100 years for the ≥65 age group. Further, 835.2 million Danish kroner of societal cost savings and 759 QALYs would be gained with a PCV21 NIP. The ICER value indicates that a PCV21 NIP would be a cost-saving dominant strategy for adults ≥65.
CONCLUSIONS: Implementing a PCV21 NIP for adults ≥65 would be a cost-effective strategy to help reduce the burden of pneumococcal disease-related morbidity and mortality in Denmark.
RESEARCH DESIGN AND METHODS: A deterministic dynamic transmission model evaluated the health impact and cost-effectiveness of a 21-valent pneumococcal conjugate vaccine (PCV; PCV21) national immunization program (NIP) compared with a 20-valent PCV (PCV20) NIP for adults ≥65 in Denmark from 2020 through 2120. Cumulative pneumococcal disease cases and deaths averted, quality-adjusted life years (QALYs), and societal healthcare costs are reported. An incremental cost-effectiveness ratio (ICER) was calculated comparing a PCV21 NIP to a PCV20 NIP.
RESULTS: Compared to a PCV20 NIP, a PCV21 NIP would avert an additional 29,309 non-bacteremic pneumococcal pneumonia (NBPP) cases, 9,625 hospitalizations (IPD and inpatient NBPP), 627 IPD cases, and 1,312 deaths over 100 years for the ≥65 age group. Further, 835.2 million Danish kroner of societal cost savings and 759 QALYs would be gained with a PCV21 NIP. The ICER value indicates that a PCV21 NIP would be a cost-saving dominant strategy for adults ≥65.
CONCLUSIONS: Implementing a PCV21 NIP for adults ≥65 would be a cost-effective strategy to help reduce the burden of pneumococcal disease-related morbidity and mortality in Denmark.